Exploratory Study to Assess the Safety and Efficacy of CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Latest Information Update: 28 Apr 2023
At a glance
- Drugs CT 0594CP (Primary)
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Adverse reactions
Most Recent Events
- 28 Apr 2023 New trial record